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Abstract
Introduction: To evaluate long-term outcomes in HIV-infected adolescents, it is important to identify ways of tracking
outcomes after transfer to a different health facility. The Department of Health (DoH) in the Western Cape Province (WCP) of
South Africa uses a single unique identifier for all patients across the health service platform. We examined adolescent
outcomes after transfer by linking data from four International epidemiology Databases to Evaluate AIDS Southern Africa
(IeDEA-SA) cohorts in the WCP with DoH data.
Methods: We included adolescents on antiretroviral therapy who transferred out of their original cohort from 10 to 19 years
of age between 2004 and 2014. The DoH conducted the linkage separately for each cohort and linked anonymized data were
then combined. The primary outcome was successful transfer defined as having a patient record at a facility other than the
original facility after the transfer date. Secondary outcomes included the proportion of patients retained, with HIV-RNA <400
copies/ml and CD4 > 500 cells/µl at 1, 2 and 3 years post-transfer.
Results: Of 460 adolescents transferred out (53% female), 72% transferred at 10–14 years old, and 79% transferred out of
tertiary facilities. Overall, 81% of patients transferred successfully at a median (interquartile range) of 56 (27–134) days
following transfer date; 95% reached the transfer site <18 months after transfer out. Among those transferring successfully,
the proportion retained decreased from 1 to 3 years post-transfer (90–84%). There was no significant difference between
transfer and 1–3 years post-transfer in the proportion of retained adolescents with HIV-RNA <400 copies/ml and CD4 > 500
cells/µl except for HIV-RNA <400 copies/ml at 3 years (86% vs. 75%; p = 0.007). The proportion virologically suppressed and
with CD4 > 500 cells/µl was significantly lower at 1 and 2 years post-transfer in those transferring at 15–19 vs. 10–14 years of
age. Using laboratory data alone over-estimated time to successful transfer.
Conclusions: Linking cohort data to health information system data allowed efficient assessment of post-transfer outcomes.
Although >80% of adolescents transferred successfully with nearly 85% of them retained for 3 years post-transfer, the decline
in the proportion virologically suppressed and poorer outcomes in older adolescents are concerns.
Keywords: HIV-1; adolescents; transfer; transition; sub-Saharan Africa; antiretroviral; data linkage
Received 14 November 2016; Accepted 15 February 2017; Published 16 May 2017
Copyright: © 2017 Davies M-A et al; licensee International AIDS Society. This is an Open Access article distributed under the terms of the Creative Commons
Attribution 3.0 Unported (CC BY 3.0) License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Introduction
There were an estimated 1.8 million HIV-infected adolescents
globally in 2015 and this population is increasing both due to
longer survival of perinatally HIV-infected children as well as
behaviourally transmitted infections at older ages [1]. With the
decline in new infant infections due to widespread coverage of
effective prevention of mother-to-child transmission, the bur-
den of paediatric HIV is shifting into adolescence [2,3]. Some
studies have reported poor retention and virologic response in
adolescents initiating HIV care and antiretroviral therapy (ART)
in resource-limited settings (RLS) [4–7]. It is therefore important
to evaluate long-term outcomes in HIV-infected adolescents.
However, collection of such data may be challenging as adoles-
cents frequently transfer care to a different facility [8]. For
example, in the International epidemiology to Evaluate AIDS-
Southern Africa (IeDEA-SA) cohort collaboration, one in four
adolescents transferred care between 10 and 13 years of age
[9]. In wealthy countries, adolescent HIV care transfer usually
involves moving from specialist paediatric HIV care to an adult
clinic and occurs when the adolescent reaches approximately
18–25 years of age, coinciding with the developmental shift
towards adulthood, hence being referred to as “adolescent
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transition” [10]. Developmentally, adolescents take more
responsibility for their own decision-making and self-care, but
it is also a time when risk-taking behaviour tends to increase.
Cohorts from Europe and North America report concerning
outcomes regarding retention, mortality and virologic suppres-
sion when HIV-infected adolescents transition to adult care,
especially among those behaviourally infected or moving to a
clinic at a different facility [11–13]. There are very limited data
on HIV-infected adolescents transitioning to adulthood in RLS
[8]. In Thailand, 73% of 67 adolescents were retained in care
between 1 and 6 years following transition to adult care at the
same institution with nearly 80% having HIV-RNA<40 copies/ml
[14]. While dedicated adolescent services in RLS report high
retention and virologic suppression [15], a transition clinic in
Uganda found only one-third of patients used services regularly,
with especially poor utilization in those not on ART [16].
In contrast to the model of care in resource-rich coun-
tries, in RLS, healthcare for HIV-infected children is decen-
tralized and mostly occurs in non-specialist primary care
facilities, with clinical officers, medical officers and nurses
being responsible for paediatric care [17–19]. Where chil-
dren do initiate HIV care and ART at a specialist paediatric
facility, they are frequently transferred from the paediatric
facility to primary care during childhood or early adoles-
cence once stable on ART [20]. This is not unique to HIV
care – in RLS including in the Western Cape Province (WCP)
of South Africa, children with a range of conditions are
usually transferred out of paediatric care when they reach
approximately 13 years of age. Hence, while patients are
leaving the specialist paediatric care environment, this may
not coincide with the time at which they transition to
adulthood and take responsibility for their own self-care.
In RLS, children receiving ART at primary care facilities
have been shown to have comparable or better retention
and virologic suppression compared to those at specialist
facilities [19,21,22]. Among young children transferring
from tertiary to primary care in the WCP, more than 80%
successfully reached the transfer site with improved CD4
and viral load responses after transfer [23]. However, there
is little data on transition/transfer outcomes of adolescents
in RLS where transfer may occur earlier during adolescence
than in wealthy countries. This lack of data is partly
because of the challenge of following adolescents after
transfer has occurred. The WCP Department of Health
(DoH) is unique in that many of its patient information
systems are uniform throughout the jurisdiction. These
systems capture data on visits to most health facilities in
the province, clinical data on laboratory, pharmacy, ART and
tuberculosis, as well as mortality and birth surveillance
(Figure 1). In order to track outcomes across disease pro-
grammes and facilities, the WCP DoH has developed a
Provincial Health Data Centre (PHDC) and patients use the
same health identifier (folder number) in all services.
IeDEA-SA includes four cohorts providing paediatric HIV
care in the WCP. The WCP PHDC therefore provides a
unique opportunity to examine patient outcomes after
transfer by linking IeDEA-SA cohort data collected at each
site to data from the PHDC information systems. Data
linkage provides an efficient and valuable means to track
outcomes in these patients, especially as on-the-ground
tracing studies are resource intensive and challenging, so
infrequently conducted in RLS. We aimed to (i) assess the
feasibility of this linkage approach for examining transfer
outcomes in HIV-infected adolescents transferring care
between 10 and 19 years of age and (ii) describe the
following outcomes: successful transfer to a different facil-
ity as well as retention within the WCP health service, viral
suppression and CD4 response for up to 3 years after
transfer.
Methods
Study population
We included data from the four IeDEA-SA cohorts providing
paediatric HIV care in WCP – two tertiary care (Tygerberg
Academic Hospital and Red Cross War Memorial Children’s
Hospital) and two primary care (Gugulethu and Khayelitsha
Community Health Centres) cohorts. These are all urban Cape
Town cohorts in both formal and informal settlement areas.
We included all adolescents on ART if they had a valid WCP
DoH folder number and were recorded as transferred out by
the above cohorts between 10 and <20 years of age from
March 2004 through December 2014. IeDEA-SA cohorts col-
lect routine patient monitoring data on demographics, clinical
outcomes and laboratory tests. These data are de-identified
and transferred annually to the IeDEA-SA Data Centres at the
Universities of Cape Town, South Africa, and Bern,
Switzerland, for inclusion in combined analyses using a stan-
dard data transfer format. All cohorts have ethics approval to
examine long-term outcomes of patients at their facilities
through linkage to other datasets and to contribute de-iden-
tified data to the IeDEA Data Centre. Waivers of informed
consent have been granted by the respective institutional
review boards as the analyses use only anonymized data
that are already collected as part of routine patient care.
The IeDEA Data Centres have ethics approval to combine
and conduct analyses on the de-identified data.
Patterns of paediatric HIV care transfer in the Western
Cape
There are various patterns of patient transfer in the context
of paediatric HIV care outlined below. Patients transferring
Figure 1. Sharing a unique health identifier (PMI) to enable sub-
sequent linkage of patient data across multiple domains.
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for any of the reasons below would be documented as
“transferred out” in the IeDEA-SA data.
● Most common is transfer of stable patients from
tertiary care specialist paediatric facilities to pri-
mary care facilities where paediatric care is largely
through clinical nurse practitioners or medical offi-
cers [20,24]. While such transfer may coincide with
later adolescence and transition to adulthood, it
most often occurs in childhood or early adoles-
cence. Nevertheless, these children and young ado-
lescents leave the protected and dedicated
paediatric care environment of a specialist facility
to the frequently busier and more generalist envir-
onment of primary care where they are seen along-
side adults, and adolescent patients may need to
assume more responsibility for self-care. This pat-
tern of transfer is very frequent in the context of
the decentralized model of HIV care in WCP where
patients should receive care at the facility closest to
their homes and the lowest level appropriate to
their disease condition [20].
● Patients may transfer from one primary care facility to
another within WCP due to patient migration or
choice, or due to ART programmes starting in facilities
closer to the patient’s home.
● Patients who are unwell or experiencing treatment
failure may be transferred from primary care up to
tertiary care to receive specialist management.
● Patients may transfer to a different province due to
patient migration.
Western Cape PHDC and linkage process
Most patient information systems are uniform throughout
the WCP public sector health service platform with the same
health identifier (folder number) being used for each patient
in all services. The shared folder number and related patient
details are referred to as the Patient Master Index (PMI),
which is hosted by a common information system used at all
major provincial hospitals and linked to all primary care and
HIV services, laboratory, and pharmacy systems through a
web-services interface (Figure 1). All laboratory test results
are digitized, and all hospitals have electronic dispensing.
The PHDC, which operates within a Microsoft SQL Server
environment, receives daily updates from these different
electronic data sources, and integrates the datasets using
the PMI to link the different records to individuals. This
provides an up-to-date clinical record per individual for facil-
ity encounters, laboratory tests undertaken and drugs dis-
pensed, regardless of the facility of origin.
To conduct the linkage, each cohort securely submitted
to the PHDC a list of folder numbers of adolescents who
had transferred out of their facility. The data were linked to
PHDC data (facility visits; admissions; CD4 and viral load
tests; pharmacy records of antiretroviral drugs dispensed).
All PHDC data linkages using identified data were per-
formed by PHDC staff who are bound by South African
provincial and national requirements around protection of
patient confidentiality. The PHDC performs de-duplication
analyses to identify situations where one individual has
been assigned more than one PMI in error. Where such
linkage can be conclusively demonstrated, outcomes data
were separately provided for linked PMI numbers, allowing
for inclusion of complete de-duplicated clinical data for
these individuals. Once linkage was complete, data were
securely returned to the individual cohorts with patient
identifying information stored separately from clinical
data. Each cohort linked the clinical data to the demo-
graphic data using study-specific identifiers, then de-identi-
fied the combined data and submitted the anonymized
dataset to the IeDEA Data Centre for analysis.
Outcomes and analysis
The primary outcome was the proportion of patients with
“successful transfer” defined as a record (visit, laboratory
test or pharmacy) at a facility other than the original facility
after the transfer-out date at the original facility. We also
examined the proportion of patients with successful trans-
fer within 18 months of the transfer-out date from the
original facility. Secondary outcomes included the following:
● Transfer delay defined as the gap in days between
transfer-out date and first record indicating success-
ful transfer.
● Proportion of patients retained, proportion with HIV-
RNA/CD4 measured, virologically suppressed (HIV-RNA
<400 copies/ml) and with CD4 absolute count >500
cells/µl at 1, 2 and 3 years post-transfer according to
age at transfer (10–14 vs. 15–19-years old).
We examined outcomes after transfer by requesting each
contributing site to link routinely collected data for trans-
ferred patients to PHDC information systems prior to trans-
ferring the anonymized data to the IeDEA-SA Data Centre.
The PHDC included data through mid-October 2016. We
considered patients “retained” if they had ≥1 visit within
6 months on either side of the time point evaluated i.e. for
retention at 1 year, an adolescent had to have ≥1 visit
between (transfer in date +365 days)  6 months. When
assessing retention for each year following the transfer in
date in those who successfully transferred, we only
included adolescents with sufficient potential follow-up
after successful transfer and before the date of PHDC
database closure for the outcome to be evaluated. For
example, when assessing retention 2 years after transfer
out, we only included adolescents who had successfully
transferred at least 2.5 years before PHDC database clo-
sure. Therefore, the number of patients in whom retention
and laboratory outcomes can be assessed is lower at 2 and
3 years after transfer. HIV-RNA and CD4 measures at each
duration following transfer were the measures taken on the
date closest to the date of successful transfer plus 1, 2 or
3 years, respectively, within a window of 6 months on
either side of the time point. We compared the proportion
of patients considered to have transferred successfully and
the transfer delay when using different sources of data
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(laboratory, pharmacy and visits) to assess the value of
different data sources when examining transfer outcomes.
All analyses were conducted in Stata13 (College Station,
Texas). We described characteristics of children at transfer
using medians with interquartile ranges and proportions for
continuous and categorical variables, respectively. As route
of infection was not recorded, we considered children peri-
natally infected if they enrolled in HIV care before 13 years
of age. We compared laboratory values at transfer with
laboratory values at each time point after transfer using
the Wilcoxon sign rank test for median CD4 count and
binomial tests for the proportion with HIV-RNA <400
copies/ml, respectively. Each comparison was limited to
children with values measured both at transfer and the
respective time point. We examined predictors of success-
ful transfer using adjusted logistic regression. We included
the following variables in the model a priori: likely perinatal
infection (indicated by enrolment in HIV care at <13 years
of age), sex, age at transfer (10–14 years vs. 15–19 years),
HIV-RNA <400 copies/ml at transfer and whether the
patient was transferring out of primary or tertiary care.
Results
Patient characteristics at transfer
A total of 460 adolescents 10–19 years (53% female) were
transferred out of their original site during the study period
(Table 1). All patients had recorded folder numbers and
could be linked to PHDC data, except in the smallest cohort,
where only 33 adolescents transferred and 9 of them (27%)
had valid recorded folder numbers and could be included in
the study. Patients transferring from that site with folder
numbers were similar to patients without folder numbers
except that they were more likely to be female (p = 0.073).
Most transfers were from tertiary care facilities (79%) with
72% of transfers during early adolescence (<15 years of
age). Ninety per cent of adolescents were considered peri-
natally infected using the definition of enrolment in HIV
care before 13 years of age. If we restricted the definition
of “perinatally infected” to adolescents who enrolled in HIV
care before 10 years of age, 69% would be considered
“perinatally infected”. However, most children enrolling
between 10 and 12-years old did so at tertiary care pae-
diatric clinics and had advanced disease suggesting long-
standing/perinatal infection. At transfer 78% of adolescents
were virologically suppressed and 64% had CD4 >500
cells/µl.
Successful transfer and outcomes after transfer
Using linked visit, laboratory and pharmacy data, 81% (95%
CI: 77–85%) of children were considered to transfer suc-
cessfully, of whom 95% linked to the transfer site within
18 months of their transfer date (Figure 2). As the intended
transfer site was not recorded in the cohort database, we
could not exclude patients who had intended to transfer
out of the province or to the private sector from our
Table 1. Characteristics of adolescents transferring between 10 and 19 years of age
Transferred successfully Not transferred successfully All adolescents
Number (%) 374 (81.3) 86 (18.7) 460 (100)
Sex
Male (n, %) 174 (46.5) 41 (47.7) 215 (46.7)
Female (n, %) 200 (53.5) 45 (52.3) 245 (53.3)
Age at enrolment*
<13 years (n, %) 338 (90.4) 72 (83.7) 410 (89.1)
≥13 years (n, %) 36 (9.6) 14 (16.3) 50 (10.9)
Age at transfer
<15 years (n, %) 267 (71.4) 65 (75.6) 332 (72.2)
15–19 years (n, %) 107 (28.6) 21 (24.4) 128 (27.8)
Cohort at transfer
Primary care 59 (15.8) 36 (41.9) 95 (20.7)
Tertiary care 315 (84.2) 50 (58.1) 365 (79.3)
HIV-RNA <400 copies/ml at transfer (n/N, %) 289/355 (81.4) 49/79 (62.0) 338/434 (77.9)
CD4 ≥ 500 cells/µl at transfer (n/N, %) 243/367 (66.2) 44/79 (55.7) 287/446 (64.3)
Median (IQR) age at ART start (years) 8.1 (5.3–10.7) 9.3 (6.6–11.7) 8.4 (5.4–10.9)
Median CD4 count at ART start (cells/µl) 299 (169–554) 241 (144–467) 289 (161–537)
Median CD4 % at ART start 13.0 (7.1–20.0) 12.7 (7.7–19.4) 12.8 (7.1–19.8)
Median (IQR) age at transfer (years) 12.9 (11.4–15.3) 12.5 (11.4–15.0) 12.8 (11.4–15.3)
Median (IQR) years on ART at transfer 6.1 (1.7–8.3) 3.9 (1.1–6.9) 5.5 (1.5–8.2)
Median CD4 count at transfer (cells/µl) 643 (411–918) 524 (227–739) 636 (387–876)
*proxy for perinatally infected
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*
Binomial test of proportions comparing proportions at each time point with values at transfer limited to patients with measurements at transfer and the respective time point
p-value (comparing proportion with VL< 400 copies/ml 
or CD4 >500 cells/µl vs proportion at transfer)
*
Number (%) of adolescents with outcome
(a)
Number of adolescents in whom outcome 
could be assessed
460
(100%)
374 
(81%)
310 
(90%)
117345 276 270 310 227
163 
(84%)
98 
(75%)
69 
(59%)
460 460
289
(81%)
355 367
220 
(80%, )
191 
(71%)
274 
(88%)
183 
(81%)
150 
(70%)
213 193 131
0.179
%02%71 %82%22%31
Percent of those retained with laboratory 
measure missing
11%5% 2%
700.0000.1821.0000.1232.0
243 
(66%)
15 
*
Binomial test of proportions comparing proportions at each time point with values at transfer limited to patients with measurements at transfer and the respective time point
p-value (comparing proportion with VL< 400 copies/ml 
or CD4 >500 cells/µl vs proportion at transfer)*
p-value (comparing proportion with VL< 400 copies/ml 
or CD4 >500 cells/µl vs proportion at transfer)*
Number (%) of adolescents with outcome
332 
(100%)
267 
(80%)
217
(83%)
231 
(93%)
Number of adolescents in whom outcome 
could be assessed
332 332 261 264 248 204 201 231
%72%81%12%71%31%21
127 
(85%)
81 
(78%)
59 
(63%)
172 164 150 104
170 
(83%)
149 
(74%)
207 
(90%)
146 
(85%)
127 
(77%)
0.027 0.324
10-14 
years of 
age at 
transfer
Number (%) of adolescents with outcome
128 
(100%)
107 
(84%)
72 
(77%)
79 
(81%)
50
 (69%)
42 
(61%)
67 
(85%)
37 
(67%)
23 
(47%)
36 
(84%)
17 
(63%)
10 
(42%)
406.0524,0066.0896,0
93
Percent of those retained with laboratory 
measure missing
2% 1%
72 69 79 55
Number of adolescents in whom outcome 
could be assessed
128 128 94 103
0.106 0.284
15-19 
years of 
age at 
transfer
191 
(72%)
52 
(50%)
824,0231,0805.0801.0
49 43 27 24
Percent of those retained with laboratory 
measure missing
%33%52%72%81%31%9%4%21
97
(b)
Figure 2. a) Per cent of all children successfully transferred and retained at 12, 24 and 36 months after successful transfer and percent
with HIV-RNA <400 copies/ml and CD4 > 500 cells/µl among those retained. b) Per cent of all children successfully transferred and
retained at 12, 24 and 36 months after successful transfer according to age group at transfer (10-14 years [solid bars] and 15-19 years
[diagonal striped bars]). Percent with HIV-RNA <400 copies/ml and CD4 > 500 cells/µl among those retained. P-values comparing
outcomes in each age group using chi2 tests are shown on the graph.
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analysis. These estimates therefore likely represent lower
bound estimates of transfer success, since we only linked to
patient data in WCP public sector. From previous analyses
of transfers in children, about 6% of transfers are outside of
the province [23] so we could assume that at least 85%
(82% of approximately 95% of patients transferring within
the province) successfully transfer. Median (interquartile
range) follow-up after successful transfer was 3.3 (2.2–
4.9) years.
Following transfer, there is a small drop-off in retention
overall from 90% (95% CI: 86–93%) at 1 year to 84% (95%
CI: 79–89%) at 3 years (Figure 2a). Retention was lower in
15–19-year olds vs. 10–14-year olds at 1 and 2 years but
similar at 3 years (Figure 2b). Of note, in 15–19-year olds
retention was higher at 2 and 3 years after transfer com-
pared to 1 year after transfer. This could represent a gap in
care following successful transfer with later re-engagement,
or could be ascribed to improving information systems such
as electronic dispensing being expanded over the last sev-
eral years. The proportion with HIV-RNA <400 copies/ml
and CD4 >500 cells/µl of those assessed was similar in years
1 and 2 but decreased at 3 years after transfer from 80%
(95%CI: 75–84%) to 75% (95%CI: 67–82%) and 71% (95%CI:
65–76%) to 59% (95%CI: 50%-68%), respectively (Figure 2a).
However, these proportions were not significantly lower
than the proportion at transfer when comparing propor-
tions in patients with values available at both time points
except for HIV-RNA <400 copies/ml at 3 years (86% vs. 75%;
p = 0.007) (Figure 2a).
The proportion with HIV-RNA <400 copies/ml and
CD4 >500 cells/µl at 1, 2 and 3 years post transfer was
consistently lower in adolescents who were older at
transfer. Although not statistically significant at 3 years
this is likely due to lack of power because of the small
number of older adolescents with sufficient potential
follow-up and laboratory measures available for analysis
(Figure 2b). The median (IQR) CD4 count declined signifi-
cantly from 654 (444–926) cells/µl at transfer to 639
(461–903) at 2 years (p = 0.034) and 580 (429–793) at
3 years (p = 0.004) (analysis restricted to patients with
CD4 measured both at transfer and the respective time
post-transfer). The proportion of patients with missing
laboratory test measurements increased between 1 and
3 years post successful transfer (from 11–20% [HIV-RNA]
and 13–28% [CD4 count]) (Figure 2a). Nevertheless,
among those retained in care but with missing HIV-RNA
at 3 years, 38% had a subsequent measurement shortly
after the 3-year window with HIV-RNA <400 copies/ml
and a further 19% had measurements at 2 years and
had been continually suppressed. Only 13% had subse-
quent HIV-RNA values that were not suppressed, while
the remaining 31% with no subsequent HIV-RNA mea-
surements either had no previous measurements or had
not been previously continuously suppressed. The
increasing proportion with missing CD4 values is in keep-
ing with South African treatment guidelines which, since
2013, recommended that CD4 monitoring should not be
done in clinically stable and virologically suppressed
patients [25]. In the 22 patients who had CD4 missing
but did have HIV-RNA measured, 21 were either virologi-
cally suppressed or had been previously continuously
suppressed with this being the first non-suppressed HIV-
RNA, so CD4 measurement would not have been
indicated.
Predictors of successful transfer
Adolescents transferring out of tertiary care facilities, those
≥15 years of age and virologically suppressed at transfer
were more likely to transfer successfully (Table 2). In con-
trast, there was no significant difference in transfer success
by likely route of infection.
Comparison of estimated successful transfer using
different data sources
The proportion of children who would be estimated to
transfer successfully using different PHDC data sources is
shown in Table 3. Using laboratory records alone, 73% of
children would be considered to transfer successfully with
63% linking to the referral site within 18 months of the
transfer out date. Corresponding values using visit records
alone were 80% and 72%, respectively, and 81% and 77%
using all data sources. The median (IQR) transfer delay was
lower using visit data than laboratory data (73[28–197] vs.
241[142–388] days), and 56 (27–134) days using all data
sources.
Discussion
This is one of the first studies examining adolescent out-
comes after transfer in RLS. In terms of transfer and
post-transfer outcomes, overall, >80% of adolescents
aged 10–19 years transferred successfully and retention
in those who transferred remained relatively high for up
to 3 years (85%). Nevertheless, the proportion of
Table 2. Logistic regression of predictors of successful trans-
fer (adjusted for all other variables in the table)
Characteristic Adjusted Odds Ratio 95% CI p-value
Gender
Male 1
Female 1.20 0.70–2.04 0.506
Original cohort
Tertiary care 1
Primary care 0.28 0.16–0.50 <0.001
VL at transfer
≥400 copies/ml 1
<400 copies/ml 2.75 1.58–4.80 <0.001
Age at enrolment*
≥13 years 1
<13 years 2.85 1.14–7.15 0.026
Age at transfer
10–14 years 1
15–19 years 1.06 1.01–1.11 0.017
*proxy for perinatal infection
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adolescents with HIV-RNA <400 copies/µl and median
CD4 count declined by 3 years following successful trans-
fer, and outcomes were consistently worse in older ado-
lescents. We found that assessment of transfer success
and long term outcomes in adolescents is feasible using
HIV cohort data linked to health information system data
such as the PHDC. Almost all transferring adolescents had
valid folder numbers, data were prepared by the cohorts
and linkage conducted by the PHDC in <4 weeks, and a
very high proportion of patients could be linked to PHDC
data.
Comparison with other studies
Patient outcomes following transfer in our study compare
favourably with studies of transfer and adolescent transi-
tion from wealthy countries, although transfer in our
study occurred at younger ages and cannot be considered
equivalent to transition to adult care. In this respect, the
poorer retention, viral load and CD4 outcomes following
transfer in those transferring between 15 and 19 years of
age in our study is a key concern. A recent US study of
patients transferring between 21 and 25 years of age
reported only 50% of patients retained at one year post-
transfer [12]. In the UK, retention of perinatally HIV-
infected adolescents transitioning to adult care at
17 years of age was higher in those transferring to adult
clinics at the same facility (92%) compared to those mov-
ing to a new facility (72%) [13]. An Italian study reported
84% retention following transfer in children and adoles-
cents 0–18-years old [26].
There are very few studies of transition/transfer out-
comes in adolescents in RLS. A study in Thailand that
transitioned adolescents to adult care in small groups
rather than individually reported 73% retention between
1 and 6 years post-transfer [14]. In our study, assuming
about 5% of adolescents transfer out of WCP [23], success
within the province is at least 85%, with nearly 85%
retention of the transferred group 3 years later, giving
overall retention of 72% – very similar to the Thailand
study. Virologic suppression was also similar at approxi-
mately 80% in both our study and the Thailand one [14].
It is understandable that virologically suppressed adoles-
cents are more likely to successfully link to transfer sites as
virologic suppression is a measure of adherence. However,
it is unclear why children transferring out of primary care
were less likely to transfer successfully. This may be
because a higher proportion of adolescents transferring
out of primary care are transferring out of the province,
or because a major reason to transfer out of primary care is
because an adolescent is unwell or has treatment failure
warranting specialist care, both of which are associated
with mortality and non-retention.
Strengths and limitations
The major strength of this study was linkage of well-curated
cohort data with PHDC data providing a very efficient way to
assess transfer and long-term outcomes in adolescents that is
not facility centric. In the absence of this linkage, follow-up of
these adolescents would be censored at the last visit at the
original site, with substantial challenges to tracking long term
outcomes. This method has broad applicability; it could also
be used to assess whether patients lost to follow-up have
silently transferred to a different facility and to examine
other health outcomes such as pregnancy incidence in HIV-
infected adolescents. In particular, the use of a combination
of different data sources (laboratory, visit and pharmacy)
enhanced outcome ascertainment and laboratory records
alone would have over-estimated the transfer delay substan-
tially. To our knowledge, this is the first analysis of transfer
outcomes during adolescence in sub-Saharan Africa. Given
increasing decentralization and task-shifting in paediatric ART
programmes across the sub-continent [19] and the growing
numbers of HIV-infected adolescents, transfer during adoles-
cence will likely become more frequent so understanding
these outcomes and identifying efficient ways to track ado-
lescents after transfer is important.
A major limitation of our study is that linkage was limited
to WCP as unique identifiers are not used nationally, so we
could not assess transfers outside the province. Similarly, the
intended transfer site was not routinely recorded by the
original cohort so we do not have an accurate measure of
the proportion of transfers out of WCP, and could not assess
whether patients transferred to the intended site within the
province. While use of data from only administrative sources
such as the PHDC allowed us to efficiently track post-transfer
outcomes, our analysis had to be limited to variables col-
lected by routine health information systems. Hence, we
could not assess the impact of other key variables such as
Table 3. Comparison of proportion of children considered successfully transferring and the transfer delay using data from
different data sources
Proportion
transferring
successfully
Proportion transferring
successfully within 18 months
Median (IQR) days between last
contact at original site and first contact
at transfer site
Visits only 80% 72% 73 (28–197)
Laboratory results only 73% 63% 241 (142–388)
Pharmacy records only* 54% 29% 451 (56–1161)
Laboratory, pharmacy and visits 81% 77% 56 (27–134)
*Low proportion with pharmacy records due to non-availability of electronic dispensing at all facilities throughout the study period.
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socio-economic status, mental health and adherence on post-
transfer outcomes. In addition, we did not have an additional
non-administrative data source (such as a tracing study), so
could not assess whether gaps in care identified in our study
were real or artefactual due to incomplete coverage of a
particular data source. Overall, only a small number of
patients transferred especially during late adolescence and
the proportion of likely behaviourally infected adolescents
was small, limiting our ability to comprehensively assess
transfer outcomes in these groups. There were relatively
small numbers of adolescents with sufficient long term
potential follow-up (i.e. transferred long enough before
PHDC database closure) to assess outcomes at 3 years after
transfer. We did not have national identity numbers of the
adolescents so did not link to the mortality registry and were
unable to determine whether mortality is an important rea-
son for non-retention. Nevertheless, at least 30–45% of
patients not retained in a particular year were not deceased
as they returned to care in the subsequent year, and we have
previously shown that mortality ascertainment in children
<15 years of age (the majority of our study) is much higher
than in adults [27]. In keeping with the aims of the review to
examine outcomes following formal transfer to another facil-
ity, and the inclusion criteria, we only examined outcomes in
patients that were formally documented as transferred out in
the IeDEA-SA data. Since transfer of paediatric and adoles-
cent patients is a key component of the model of HIV care in
the Western Cape, documentation of transfer is generally
reliable. However, it is possible that some patients who
transferred were not correctly coded and thus excluded
from our study. In addition, we did not examine “silent
transfer” where patients appear LTFU at the original facility
but have themselves resumed care elsewhere without being
formally transferred.
Finally, the completeness of HIV-RNA testing decreased over
time limiting assessment of HIV-RNA suppression. Reasons for
reduced completeness of HIV-RNA testing are unclear; it is
possible that HIV-RNA testing is not prioritized in patients
who have been stable and virologically suppressed on ART
for a long time or that visit spacing is greater in stable patients
with fewer opportunities to test HIV-RNA. The fact that nearly
60% of patients with missing HIV-RNA data at 3 years post-
transfer either had subsequent values indicating suppression
or were previously continuously suppressed would support
this. It is possible that adolescents who were unwell or
known to have poor adherence underwent laboratory testing
more frequently, biasing results towards poorer outcomes.
Nevertheless, the finding that completeness of routine HIV-
RNA testing decreased at longer follow-up durations is impor-
tant in itself.
Conclusions
Our study demonstrates the enormous potential for asses-
sing long-term outcomes of adolescents using linked health
information system data such as the PHDC. The proportion
of adolescents with successful transfer and retention for up
to 3 years was reasonable overall and comparable with
other studies from RLS. Nevertheless, the outcomes of
those not retained need to be explored. The decline in
virologic suppression and poorer outcomes in older adoles-
cents are concerns.
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